ContraVir Pharmaceuticals,Inc. (NASDAQ:CTRV) Files An 8-K Other EventsItem 8.01 Other Events
On October24, 2017, ContraVir Pharmaceuticals,Inc. (the “Company”) issued a press release announcing that it will utilize preclinical services from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to characterize the antiviral activity of CRV431 in a humanized mouse model of hepatitis B virus infection.
The press release is attached as Exhibit99.1 to this report on Form8-K and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits
(d)Exhibits
|
99.1 |
ContraVir Pharmaceuticals,Inc. Press Release dated October24, 2017 |
ContraVir Pharmaceuticals, Inc. ExhibitEX-99.1 2 a17-24404_1ex99d1.htm EX-99.1 Exhibit 99.1 ContraVir Pharmaceuticals Announces National Institutes of Health Funded Study on Antiviral Activity of CRV431 EDISON,…To view the full exhibit click here
About ContraVir Pharmaceuticals,Inc. (NASDAQ:CTRV)
ContraVir Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development of antiviral drugs for the treatment of Hepatitis B virus (HBV) infections. The Company develops a range of compounds to treat HBV infection, which include CMX157 and CRV431. The Company is also developing an antiviral asset, FV-100. The Company’s CMX157 is a lipid acyclic nucleoside phosphonate that delivers intracellular concentrations of the active antiviral agent tenofovir diphosphate. The Company has completed a Phase I clinical trial of CMX157. The Company’s CRV431 drug candidate is designed to target cyclophilins, which are a class of proteins. CRV431 inhibits the role of host cyclophilins and interferes in the propagation of the viruses. The Company’s FV-100 is an orally available, small molecule, nucleoside analogue pro-drug of CF-1743, which is used for the treatment of herpes zoster. It has developed FV-100 for the treatment of shingles.